Chromatographic processes and purified compounds thereof
A chromatographic method and a mixture technology, which can be applied to ion pair reagents in the field of reversed-phase preparative chromatography, and can solve problems such as resolution reduction.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0076] Crude insulin aspart material of ~75% purity was diluted 10-fold with purified water before adding IPA to a final concentration of 5%. in Kromasil TM ( -13μ-C8) column to purify the crude mixture. Mobile phase A was 1% hexanesulfonic acid (HSA) (w / v) in 250 mM sodium acetate, pH 4.0 and mobile phase B was isopropanol. In mobile phase A, a gradient elution of 18%-22% mobile phase B was performed over 20 column volumes. The addition of HSA effectively removes the desocta (desocta) insulin aspart and also observes that the des leader sequence desB-arginine insulin aspart precursor is reduced from a level of -2.77% to less than 0.27%, and the overall purity achieved is ~97.85%.
[0077] Control 2
[0078] Crude insulin aspart material of ~75% purity was diluted 10-fold with purified water, then ethanol was added to a final concentration of 10%. in Kromasil TM ( -13μ-C8) column to purify the crude mixture. Mobile phase A was 25 mM ammonium sulfate in 250 mM sodium...
Embodiment 2
[0080] Crude insulin aspart material of ~75% purity was diluted 10-fold with purified water, then ethanol was added to a final concentration of 10%. in Kromasil TM ( -13μ-C8) column to purify the crude mixture. Mobile phase A was 1% hexanesulfonic acid (HSA) (w / v) in 250 mM sodium acetate in 25 mM ammonium sulfate, pH 4.0 and mobile phase B was ethanol. A gradient elution of 25%-35% of mobile phase B in mobile phase A was performed over 20 column volumes. Addition of HSA reduced the des leader sequence desB-arginine insulin aspart precursor from a level of -3% to less than 0.3%. The desocta insulin aspart was completely removed and the level of monoglycosylated insulin aspart decreased from -2% to 0.3%. The overall purity achieved was -98%.
[0081] Control 3
[0082] Crude insulin aspart material of ~67% purity was diluted 10-fold with purified water, then methanol was added to a final concentration of 10%. in Kromasil TM ( -13μ-C8) column to purify the crude mix...
Embodiment 3
[0084] Crude insulin aspart material of ~67% purity was diluted 10-fold with purified water, then methanol was added to a final concentration of 10%. in Kromasil TM ( -13μ-C8) column to purify the crude mixture. Mobile phase A was 1% hexanesulfonic acid (HSA) (w / v) in 250 mM ammonium acetate in 25 mM ammonium sulfate, pH 4.0 and mobile phase B was methanol. A gradient elution of 55%-65% of mobile phase B was performed in mobile phase A over 20 column volumes. Addition of HSA purified the des leader sequence desB-arginine insulin aspart precursor from a level of -2% to less than 1%. The monoglycosylated insulin aspart impurity was reduced from 3% to less than 0.5%. Desocta (de-eight) insulin aspart decreased from -10% to less than -2%. The overall purity achieved was -92%.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com